Skip to main
DOCS
DOCS logo

Doximity (DOCS) Stock Forecast & Price Target

Doximity (DOCS) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 28%
Hold 39%
Sell 6%
Strong Sell 6%

Bulls say

Doximity Inc has demonstrated significant growth, particularly in its point-of-care (POC) and formulary offerings, which experienced over 100% growth during the most recent buying season, indicating strong demand among medical professionals. Following recent positive developments, the company’s shares have seen a modest increase of 3.2% since early September, reflecting growing investor confidence. Additionally, Doximity's second-quarter guidance appears attainable, with the potential for upside, bolstered by increased visibility from expanded offerings and heightened upfront buying activity.

Bears say

Doximity Inc is experiencing negative financial pressures due to uncertainty in the economic environment, which has resulted in downward guidance revisions from its pharmaceutical clients for fiscal years 2023 and 2024. The company's stock is perceived as expensive relative to its software peers, leading to potential volatility should the firm fail to meet high investor expectations. Additionally, there is significant scrutiny on Doximity's financial performance, and any failure to deliver positive results or raise guidance may be regarded as a disappointment in the market.

Doximity (DOCS) has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 28% recommend Buy, 39% suggest Holding, 6% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Doximity (DOCS) Forecast

Analysts have given Doximity (DOCS) a Buy based on their latest research and market trends.

According to 18 analysts, Doximity (DOCS) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.39, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.39, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Doximity (DOCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.